glp-1 drugs sleep apnea Treatment Therapeutic potential of GLP-1RAs in

However, the synthetic version lasts longer in the body

71.2 lbs on average) Retatrutide 9mg: 26.4% body weight reduction Tirzepatide/Zepbound (Phase 3 comparison, not head-to-head): ~20.9% Semaglutide/Wegovy (Phase 3 comparison, not head-to-head): ~14.9% Placebo: ~2.1% Note: These figures come from separate Phase 3 trials and are not direct head-to-head comparisons

Ethics declarations Conflicts of Interest Financial interests: ZM has stock in Novo Nordisk Pharmaceuticals and served as a consultant for Neptune Medical

The SURMOUNT-1 trial tested the ability of tirzepatide to produce weight loss in people with obesity who do not have diabetes

These professionals caution that doctors should closely monitor Zepbound patients and consider treatment approaches that gradually impact blood sugar levels instead